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12 New drugs for the treatment of human leishmaniasis are urgently needed, considering 
 
13 the limitations of current available options. However, pre-clinical evaluation of drug candidates 
 
14 for leishmaniasis is challenging. The use of luciferase-expressing parasites for parasite load 
 
15 detection is a potentially powerful tool to accelerate the drug discovery process. We have 
 
16 previously described the use of Leishmania amazonensis mutants expressing firefly luciferase 
 
17 (Luc2) for drug testing. Here, we describe three new mutant L. amazonensis lines that express 
 
18 different variants of luciferases: NanoLuc, NanoLuc-PEST and RedLuc. These mutants were 
 
19 evaluated in drug screening protocols. NanoLuc-parasites, in spite of high bioluminescence 
 
20 intensity in vitro, were shown to be inadequate in discriminating between live and dead 
 
21 parasites. Bioluminescence detection from intracellular amastigotes expressing NanoLuc- 
 
22 PEST, RedLuc or Luc2 proved more reliable than microscopy to determine parasite killing. 
 
23 Increased sensitivity was observed in vivo with RedLuc-expressing parasites as compared to 
 
24 NanoLuc-expressing L. amazonensis. Our data indicates that NanoLuc is not suitable for in 
 
25 vivo parasite burden determination. Additionally, RedLuc and the conventional luciferase Luc2 
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31 1. Introduction 
 
32 The leishmaniases are a complex group of devastating diseases with a wide clinical 
 
33 spectrum varying from self-healing tegumentary to fatal visceral forms. Over 20 species of 
 
34 Leishmania  spp.  are  pathogenic  to  humans  leading  to  variable  clinical  manifestations 
 
35 depending on the parasite species and host immunological response. Within the tegumentary 
 
36 form,  the  disease  can  be  further  classified  in  cutaneous,  mucocutaneous,  diffuse  and 
 
37 disseminated leishmaniasis (Burza et al., 2018). Leishmania (Leishmania) amazonensis is 
 
38 one of the most prevalent agents of human cutaneous leishmaniasis (CL) in the Amazon 
 
39 region of Brazil. It is also the main etiological agent of diffuse cutaneous leishmaniasis (DCL) 
 
40 in South America (Convit et al., 1993), a rare and aggressive form of disease characterized 
 
41 by the appearance of multiple non-tender and non-ulcerating papules or nodules widespread 
 
42 in the body. DCL is a chronic disease and is considered refractory to the current available anti- 
 
43 Leishmania therapeutic arsenal (Zerpa et al., 2007). 
 
44 The  parasite  can  be  transmitted  by  several  species  of  female  hematophagous 
 
45 sandflies, most of them within the genus Phlebotomus, in the Old World, and Lutzomyia, in 
 
46 the New World (Akhoundi et al., 2016). Leishmaniases are distributed worldwide and endemic 
 
47 in over 90 countries or territories. According to the World Health Organization, the annual 
 
48 incidence of the disease is approximately 1 million new cases (Bern, Desjeux, Cano, & Alvar, 
 
49 2012; WHO, 2015). 
 
50 The treatment of leishmaniases is limited to a few drugs and most of them have been 
 
51 in use for a long time without significant upgrading (Uliana et al., 2017). The therapeutic 
 
52 arsenal currently available includes pentavalent antimonials, amphotericin B, pentamidine, 
 
53 miltefosine and paromomycin. Miltefosine is the only drug which is administered orally (Sundar 
 
54 and Olliaro, 2007), whereas all the others must necessarily be administered parenterally. All 
 
55 those  drugs  may  induce  serious  side  effects,  ranging  from  nephro-hepatotoxicity  to 
 
56 teratogenicity  (Sundar  and  Singh,  2017).  The  toxicity  is  even  more  pronounced  in 
 
57 malnourished  patients,  a  common  occurrence  with  advanced  visceral  leishmaniasis. 
 





59 (Ponte-Sucre et al., 2017). Thus, the identification of new drugs for leishmaniasis treatment 
 
60 with better efficacy and safety profiles is an urgent issue. 
 
61 Preclinical drug development against leishmaniasis includes in vitro and in vivo tests. 
 
62 In vitro tests are preferably performed against the intracellular amastigote stage and in vivo 
 
63 tests  employ  animal  models,  mostly  mice  and  hamsters.  The  use  of  reporter  proteins 
 
64 detectable in intact animals represented a great advance for the challenging demonstration of 
 
65 drug efficacy of antileishmanial compounds in experimental models of the disease (Calvo- 
 
66 Alvarez et al., 2018; Jaiswal et al., 2016; Rocha et al., 2013). Furthermore, the strategy 
 
67 addresses the important ethical aspects of reducing the number of animals needed for each 
 
68 experiment as well as refining the handling and information derived from each animal (two out 
 
69 of the 3Rs advocated for ethical pre-clinical research. We have previously employed mutant 
 
70 parasite lines expressing a modified firefly luciferase as an experimental tool for testing 
 
71 candidate compounds in vitro and in vivo (Reimão et al., 2015, 2013; Trinconi et al., 2016). 
 
72 Luciferases are a class of enzymes commonly found in nature in fireflies and in several 
 
73 marine organisms, such as jellyfish or copepods, that generates light in the presence of a 
 
74 specific  substrate  (Avci  et  al.,  2018;  Yan  et  al.,  2019).  Natural  luciferases  have  been 
 
75 genetically modified to improve their specific activity, through increased intensity of light 
 
76 production,  and/or  altered  wavelength  to  improve  detection.  Amongst  many  modified 
 
77 luciferases already produced, three of these were chosen for the analysis described here: 
 
78 RedLuc (RL), NanoLuc (NL) and its variation NanoLuc-PEST (NLP). NL and NLP were derived 
 
79 from Oluc, a luciferase isolated from the deep-sea shrimp (Oplophorus gracilirostris) (Hall et 
 
80 al., 2012). NL was shown to achieve greater efficiency than the parent protein in the presence 
 
81 of furimazine, its appropriate substrate, modified from coelenterazine (Hall et al. 2012). 
 
82 Furthermore, NL’s intracellular half-life of 6 hours leads to intracellular accumulation of the 
 
83 enzyme, which also potentiates light emission. NLP was obtained by inserting a PEST motif 
 
84 (García-Alai et al., 2006; Rechsteiner and Rogers, 1996) into the C-terminus region of the 
 
85 protein, resulting in a shorter intracellular half-life of about 20 minutes. RedLuc, a red-shifted 
 





87 isoleucine by a valine in the position 48 (p.I48V), which modifies the substrate (luciferin) 
 
88 cleavage, resulting in the production of light with a wavelength above 600 nm (Branchini et al., 
 
89 2005a). Long wavelength light can penetrate more easily in tissue barriers, which could 
 
90 potentially enhance the sensitivity detection of lower parasite burdens. 
 
91 Here, we described the application of these modified luciferases (NL, NLP and RL) in 
 




94 2. Materials and Methods 
 
95 2.1 Parasites 
 
96 Wild-type Leishmania amazonensis (MHOM/BR/1973/M2269) was cultivated at 25ºC 
 
97 in 199 culture medium (Sigma-Aldrich, St. Louis, MO, USA), complemented with HEPES 40 
 
98 mM, pH 7.4, adenine 0.1 mM, hemin 0.005% and supplemented with heat-inactivated bovine 
 
99 foetal  serum  10%  (Gibco®),  and  penicillin/streptomycin  100µg/ml.  A  mutant  line  of  L. 
 
100 amazonensis expressing Luc2, obtained as described (Reimão et al., 2015), was grown in 
 
101 media supplemented with 32 µg/ml hygromycin. Mutant lines obtained in this work were 
 




104 2.2. Generation of L. amazonensis line expressing the modified luciferases 
 
105 NL, NLP and RL constructs were obtained by cloning NanoLuc (616 bb), NanoLuc- 
 
106 PEST (639 bp) and RedLuc (1647 bp) ORFs into the pSSU-Neo plasmid, which contains 
 
107 complementary sequences to the Leishmania small subunit ribosomal DNA and a neomycin 
 
108 resistance encoding gene (Berry et al., 2018). Upon transfection, the linearized plasmid was 
 
109 expected to integrate into the parasite genome. 
 
110 Promastigotes were transfected as previously described by Coburn et al.(1991) using 
 
111 5  µg  of  linearized  insert.  After  24  hours,  the  selection  drug  (G418)  was  added  to  a 
 
112 concentration of 32 µg/ml. Cultures were plated on semi-solid M199 medium supplemented 
 
113 with 1.2 μg/mL biopterin, 1% agar, 2% urine and 32 μg/mL G418 for clone selection. Isolated 
 





115 through PCR amplification with primers complementary to sequences inside and outside the 
 
116 transfected   cassette.   Primers   S1   (5’-GATCTGGTTGATTCTGCCAG-3’)   and   S4   (5’- 
 
117 GATCCAGCTGCAGGTTCACC-3’) anneal to the SSU rDNA sequence (Uliana et al., 1991) 
 
118 flanking the insertion sites, and primers NanoLuc-REV (5’ TACCAGTGTGCCATAGTGCA 3’), 
 
119 RedLuc-REV (5’ ACGATGGTCTTGATGGTGGT 3’) and Neo-FOR (5’ 
 




122 2.3. Bioluminescence detection assay 
 
123 Logarithmic phase promastigotes were washed and suspended in PBS to a final 
 
124 density of 106 promastigotes/mL. Parasites were serially diluted in final volumes of 100 µL and 
 
125 incubated in lysis buffer containing either furimazine (NanoGlo Assay System, Promega), for 
 
126 mutants expressing NL and NLP, or luciferin (One-Glo luciferase Assay System, Promega), 
 
127 for mutants expressing RL and Luc2. Furimazine was added to the lysis buffer in a 1:200 ratio 
 
128 and luciferin was added in a 1:5 ratio. Bioluminescence was measured using a PolarStar 
 




131 2.4. Susceptibility assays of intracellular amastigotes 
 
132 Bone marrow-derived macrophages (BMDM) were obtained as described (Reimão et 
 
133 al., 2015) and plated in white 96-well plates (8x104  cells/well) or in 24-well plates (3x105 
 
134 cells/well) with round glass coverslips applied to the bottom of the wells. After incubation for 
 
135 24 hours at 37ºC in a 5% CO2   atmosphere, cells were infected with stationary phase 
 
136 promastigotes (fourth day of culture) in a proportion of 20 parasites: 1 macrophage. After 4 
 
137 hours incubation at 34ºC, cultures were washed to remove the remaining free promastigotes. 
 
138 Fresh medium containing several concentrations of miltefosine (Sigma-Aldrich), varying from 
 
139 1 to 30 µM, was added and the plates were incubated for 96 hours at 34ºC. The supernatant 
 
140 was discarded, and luciferase substrates were added to the 96-well plate as described in the 
 
141 section 2.3. After homogenization, light production was detected in a PolarStar Omega 
 





143 the ratio of treated/untreated cells. Macrophages cultivated in round coverslips were fixed with 
 
144 50% methanol in PBS and stained with the Romanowsky type Instant Prov kit (Newprov, 
 
145 Pinhais, PR, Brazil). The ratio of infected cells was calculated by counting 100 macrophages 
 
146 per replicate. Half maximal inhibitory concentration (IC50) was determined from 
 
147 bioluminescence and microscopy assays by sigmoidal regression of the dose-response 
 
148 curves using GraphPad Prism 8 software (CA, USA). Experiments were performed in triplicate 
 




151 2.5. Mice infection and parasite quantification 
 
152 Animal experiments were approved by the Ethics Committee for Animal 
 
153 Experimentation (Protocol 178/2012) in agreement with the guidelines of the Sociedade 
 
154 Brasileira de Ciência de Animais de Laboratório (SBCAL) and of the Conselho Nacional de 
 
155 Controle da Experimentação Animal (CONCEA). 
 
156 Female BALB/c mice (30 to 60 days-old) were inoculated subcutaneously with 106 
 
157 stationary-phase promastigotes of La-NL, La-RL or La-Luc2 in the left hind footpad. Lesion 
 
158 development was followed up weekly. Retrieval and purification of amastigotes from lesions 
 
159 was  done  as  described  previously  (Uliana  et  al.,  1999).  Quantification  of  amastigotes 
 
160 recovered from lesions was performed by limiting dilution (Lima et al., 1997). Determination of 
 
161 parasite burden was calculated using the formula LDAU = GM x RF (Calvo-Álvarez et al., 
 
162 2015), in which LDAU is the parasite burden indicated in limiting dilution assay units, GM is 
 
163 the geometric mean of titer from the replicates and RF is the reciprocal fraction of the 
 
164 homogenized lesion added to the first well. In this formula, titter is the last dilution where live 
 
165 parasites were observed. 
 
166 Bioluminescence quantification in live animals was performed as described (Reimão 
 
167 et al., 2013). Imaging was performed after intraperitoneal administration of 75 mg/kg luciferin 
 
168 (VivoGloTM, Promega) or 1:40 diluted furimazine (NanoGloTM, Promega) in sterile PBS and in 
 
169 100 µl final volume. Animals were anesthetized under a 2.5% isoflurane atmosphere and 
 





171 during imaging. Images were acquired 15 minutes after substrate administration using an IVIS 
 
172 Spectrum (Caliper Life Sciences) with 2 minutes exposure time. Bioluminescence readings for 
 
173 the  whole  animal  were  obtained.  A  region  of  interest  (ROI)  was  defined  as  a  region 
 
174 encompassing an infected footpad. The same ROI (shape and size) was used to quantify 
 
175 measured  light  units  in  all  animals  studied.  Average  radiance  (photons/second/square 
 
176 centimetre/steradian)  was  quantified  by  Living  Image  4.3.1  (Caliper  Life  Sciences), 
 
177 representing total photon emission from a ROI. A bioluminescence background was initially 
 
178 obtained  using  the  same  ROI  in  an  uninfected  mouse.  Alternatively,  background  was 
 
179 measured using the ROI positioned at the contralateral uninfected footpad. The background 
 
180 value was subtracted from all infected footpad readings. Pseudocolor imaging was generated 
 
181 based on the photon signal to represent light intensity from the infected footpads, ranging from 
 
182 red to blue meaning the most to the least intense. 
 
183 For immediate quantification of light production by parasites inoculated in mice tissues, 
 
184 105  stationary-phase promastigotes or amastigotes purified from lesions were inoculated in 
 
185 the left hind footpad and animals were imaged one-hour post-injection. 
 
186 Parasite burden of infected mice was also evaluated by ex vivo bioluminescence. For 
 
187 these assays, the material recovered from lesions was suspended in 2 mL PBS and 20 µL 
 
188 from the total amastigote extract of each infected animal was incubated in the presence of the 
 




191 2.6. Statistical analysis 
 
192 All statistical analyses were performed by GraphPad Prisma 8 (CA, USA), using 
193 ANOVA  one-way  test  and  multiple  comparisons  Dunnett’s  test.  P  values  ⩽  0.05  were 




196 3. Results and Discussion 
 
197 3.1. Generation and phenotypic characterization of L. amazonensis mutants expressing 
 





199 Constructs  containing  the  modified  luciferase  genes  were  double  digested  with 
 
200 endonucleases PacI and PmeI, to linearize the cassette. Purified inserts (Fig. 1A) were 
 
201 transfected into wild-type (WT) L. amazonensis to generate mutants expressing NL (La-NL), 
 
202 NLP (La-NLP) and RL (La-RL). Integration into the small subunit rDNA (SSU) gene was 
 
203 assessed by PCR (Figure 1B). Primers for SSU sequences upstream and downstream to the 
 
204 expected integration region were designed and paired with primers corresponding to the 
 
205 luciferase gene or drug resistance marker (Fig. 1A). PCR products with the expected sizes 
 
206 confirmed the integration of the linearized DNA fragment in the expected locus (Fig. 1B). 
 
207 Clones were obtained and their growth curves were characterized. The growth of these 
 
208 transfected parasites was indistinguishable from the WT parasites (Fig. 1C), indicating that 
 





212 Fig. 1. Generation of L. amazonensis transgenic lines expressing modified luciferases. 
213 (A) Schematic representation of the linear cassette integrated into the SSU rDNA locus. SSU: 
214 small subunit rDNA; 5’/3’ SSU: SSU homologous regions included in the cassette; LUC: 
215 coding sequence of modified luciferases; CPB IR: L. mexicana cysteine protease B intergenic 
216 region; neo: neomycin-phosphotransferase gene; arrows: primers used for PCR. (B) PCR 





218 genomic DNA with the pairs of primers S1/Red-REV (lane 1), S1/Nano-REV (lanes 2 and 3) 
219 and S4/Neo-FOR (lanes 4 to 6). (C) Growth curve of transfected and wild-type parasites. 
220 Results  are  the  mean  and  standard  deviation  of  a  representative  experiment  of  three 
221 independent experiments. 
222 
 
223 The infectivity of L. amazonensis mutant lines in vitro was tested using BMDM. Cells 
 
224 were infected with stationary-phase promastigotes and maintained in culture for 48 hours. The 
 
225 percentage of infected macrophages and the number of amastigotes per macrophage were 
 
226 determined by optical microscopy and compared to infections with the WT parasite (Table 1). 
 




229 Table 1. Evaluation of BMDM infection by WT and mutant L. amazonensis lines expressing 
 
230 modified luciferases. 
 
 
Infection (%) Amastigotes/MØ 
 
 
La-WT 56.6 ± 4,36 2.8 ± 0.3 
 
La-NL 47.6 ± 4,04 2.0 ± 0.2 
 
La-NLP 44.4 ± 3,78 1.9 ± 0.05 
 





232 The infectivity in vivo of each mutant line was evaluated in the BALB/c mice model. 
 
233 Lesion development in mice infected with the mutant lines was delayed when compared to 
 
234 WT parasites (Supplementary Material Fig. S1). This reduced virulence could be related to 
 
235 the number of in vitro parasite sub-cultures (Magalhâes et al., 2014); however, repeated 
 
236 infections in mice did not accelerate lesion development. Although the La-Luc2 line, previously 
 
237 obtained by the same method, maintained its infectivity profile, the possibility of impairment of 
 
238 the in vivo fitness of luciferase mutant parasites by the expression of those particular proteins 
 
239 cannot be excluded at present. Other studies in L. infantum expressing red-shifted luciferases 
 
240 have been done and did not report infectivity changes (Álvarez-Velilla et al., 2019; Eberhardt 
 







243 2.2. Biouminescence of promastigotes expressing NL, NLP and RL 
 
244 Luciferase activity of mutant lines was evaluated by analysing light production of 
 
245 serially diluted promastigotes incubated in the presence of their respective substrates (Fig. 
 
246 2A). Promastigotes expressing the conventional luciferase Luc2 (Trinconi et al., 2018) were 
 
247 also   evaluated   and   used   as   a   reference.   Light   emission,   expressed   in   relative 
 
248 bioluminescence units (RLU), was linearly correlated with the number of parasites (r2  > 
 
249 0.9894). NL-expressing parasites were the brightest with light output up to 1000-fold higher 
 
250 than NLP and over 100-fold higher than RL and Luc2 (Fig. 2). NLP produced the narrowest 
 
251 range of light intensity output throughout the curve. The sensitivity for detecting RL-expressing 
 
252 parasites was higher than Luc2 when 100 or less parasites were assayed. The curve profiles 
 
253 for RL and Luc2 promastigotes overlapped when more than 1000 parasites were evaluated. 
 
254 The detection limits for light production by NL, NLP and RL were 1, 10 and 10 parasites, 
 
255 respectively, while 100 parasites were necessary to detect Luc2 bioluminescence. 
 
256 Light output from these parasites increased over the course of 60 minutes after 
 
257 substrate  addition,  but  maintained  the  bioluminescence  curve  profiles  (Supplementary 
 







260 Figure 2. Luciferase activity in promastigotes of L. amazonensis transfected lines. 
261 Promastigotes were serially diluted and bioluminescence was measured 10 minutes after 
262 substrate  addition.  Results  are  the  mean  and  standard  deviation  of  a  representative 
263 experiment of three independent experiments. RLU: relative light units. 
264 
265 La-NL and La-NLP light emission patterns were in agreement with findings described 
 
266 by Hall et al. (2012), who developed NL and its derivatives through enzyme optimization and 
 
267 coelenterazine modification. An intracellular half-life of at least 6 hours for the NL protein, as 
 
268 opposed to 3 hours for Luc2 (Thorne et al., 2010), leads to NL accumulation in eukaryotic cells 
 
269 and, in theory, to a greater light production. In fact, NL half-life in L. mexicana mutant lines 
 
270 was demonstrated to be greater than 8 hours (Berry et al., 2018). Therefore, NL demonstrated 
 
271 better in vitro performance in comparison to all the other luciferases tested with a light 
 
272 emission 100 to 1000 times more intense, including the conventional luciferase, Luc2. 
 
273 On the other hand, NL slow kinetics of decay made it too stable to be used in 
 
274 promastigote viability assays, which was also seen in NL-expressing L. mexicana parasites 
 
275 (Berry  et  al.,  2018).  For  example,  in  conventional  24-hour  assays  using  increasing 
 
276 concentrations of amphotericin B against promastigotes expressing NL, it was not possible to 
 
277 detect the expected decline in light intensity in treated parasites (Supplementary Material 
 
278 Figure S3). For that reason, further in vitro experiments were performed using NLP, RL and 
 




281 2.3. Drug susceptibility testing in intracellular amastigotes 
 
282 To test these mutant lines in drug susceptibility assays, macrophages infected with La- 
 
283 NLP, La-RL and La-Luc2 were treated with different concentrations of miltefosine (Fig. 3 and 
 
284 Table 2) and the percentage of infected macrophages was determined after 72h by standard 
 
285 microscopy or bioluminescence intensity. Miltefosine was chosen given its good activity 
 
286 against L. amazonensis in vitro and in vivo (Coelho et al., 2014). The calculated IC50 values 
 
287 were   statistically   similar   between   the   mutants   for   both   methods   (Table   2).   The 
 
288 bioluminescence assay produced robust dose-response curves, consistent in all mutants. All 
 





290 drug susceptibility in intracellular amastigotes (Fig. 3B). The results determined through 
 
291 optical microscopy revealed wider standard deviations and therefore higher variability (Fig. 
 
292 3A). This can be explained by the method’s limitations, such as the examiner’s choice of fields 
 





296 Figure 3. Comparison of bioluminescence and microscopy for the evaluation of drug 
297 susceptibility. Macrophages infected with La-NLP, La-RL and La-Luc2 were treated with 
298 increasing concentrations of miltefosine for 72 hours. Parasite viability was determined using 
299 microscopy  (A)  and  bioluminescence-based  (B)  techniques.  Viability  was  calculated  in 
300 reference to the untreated control, considered as 100% viable, for each line. Data are mean 
301 and standard deviation of at least three independent experiments. 
302 
 





Lines Bioluminescencea Microscopya 
 
 
La-NLP 6.96 ± 0.99 11.85 ± 3.32 
 
La-RL 7.67 ± 1.46 12.4 ± 3.36 
 





306 a Results are the average and standard error of the mean (SEM) of at least three 
 







309 We showed that NLP, RL and Luc2 were equally able to report amastigote viability. 
 
310 Interestingly, light intensity from La-NLP and La-RL in intracellular amastigotes were higher 
 
311 than light emitted by La-Luc2 (Supplementary Material Figure S4) while the opposite was 
 
312 observed for promastigotes (Fig. 2, Supp. Fig. S2). A distinct rate of NLP/RL protein or RNA 
 
313 degradation in amastigotes might explain this observation. The cassettes with NLP and RL 
 
314 genes  contain  the  L.  mexicana  cysteine  protease  B  2.8  3’  untranslated  region  (UTR), 
 
315 downstream to the NLP or RL genes. On the other hand, the Luc2 cassette has the tubulin 3’ 
 
316 UTR downstream to the coding sequence. The CPB UTR, originally derived from a stage- 
 
317 regulated gene, may be driving this increased bioluminescence in amastigotes (Mißlitz et al., 
 




320 2.4. Comparison of modified luciferases in an in vivo model 
 
321 In order to compare the in vivo bioluminescence of the modified luciferases, mutant 
 
322 lines with higher in vitro light emission - La-NL and La-RL - were selected. BALB/c mice were 
 
323 infected with La-NL and La-RL and parasite load was evaluated by bioimaging and limiting 
 
324 dilution once lesions were well established. Parasite burden determined by limiting dilution 
 
325 was at least 10-fold higher in La-NL-infected animals than in La-RL-infected mice (Figure 4B). 
 
326 Conversely, bioluminescence detected from La-RL infected animals was up to 1000-fold 
 
327 greater than light from La-NL mice (Figure 4A and 4B). Amastigotes freshly extracted from 
 
328 lesions were also used to determine ex vivo bioluminescence and qualitatively compare the 
 
329 parasite burden between infected animals (Figure 4C). In vitro light emission in the La-NL 
 
330 lesion extracts was higher than in La-RL lesions, confirming the higher parasite burden of La- 
 
331 NL-infected mice detected by limiting dilution. The ratio between the number of amastigotes 
 
332 detected in the limiting dilution assay by the relative light units detected by bioimaging was 
 
333 used  as  an  arbitrary  measure  of  in  vivo  sensitivity  (Fig.  4D).  The  putative  number  of 
 
334 amastigotes necessary to emit one RLU in vivo was 1000-fold greater for La-NL than La-RL. 
 
335 Light produced by the reaction of RL and its substrate is emitted within a narrow 
 





337 2010). NL, on the other hand, produces a narrow spectrum at 450 nm. Results shown here 
 
338 are consistent with the previous understanding that La-RL derived light may overcome tissue 
 
339 barriers more efficiently than light produced by La-NL. Our experiments showed that animals 
 
340 infected with La-RL that developed lesions with approximately 106 parasites displayed greater 
 





344 Figure 4. Comparison of in vivo and ex vivo bioluminescence emission by La-NL and 
345 La-RL-infected  mice.  BALB/c  mice  (n  =  3)  were  inoculated  with  106   La-NL  or  La-RL 
346 promastigotes at the left hind footpad. The parasite burden was evaluated at the 31st week 
347 post infection by in vivo bioluminescence imaging (A and B), limiting dilution (B) and ex vivo 
348 bioluminescence  (C).  The  putative  number  of  amastigotes  per  RLU  captured  during 
349 bioimaging was calculated as the ratio between amastigotes detected by limiting dilution and 
350 relative light units (D). IVIS: in vivo imaging system; LDAU: limiting dilution assay units, 
351 meaning total number of amastigotes in the footpad; RLU: relative light units. 
352 
353 Considering the in vivo performance of La-RL, the mutant line was moved forward to 
 
354 be compared with Luc2, the conventional firefly luciferase. La-RL or La-Luc2 infected mice 
 
355 were evaluated nine weeks post infection by bioimaging and limiting dilution (Fig. 5A and B). 
 
356 A slower progression in lesion size was observed in the group infected with La-RL (Fig. 5D). 
 





358 infections compared with La-RL-infected mice (Fig. 5B). A bioluminescence pattern congruent 
 
359 with  the  limiting  dilution  data  was  observed  (Fig.  5A  and  B).  The  ex  vivo  amastigote 
 
360 bioluminescence assay confirmed the difference in parasite burden between groups with a 
 
361 more uniform signal within the group (Fig. 5C) compared to bioimaging and limiting dilution 
 




























365 Figure 5. In vivo and ex vivo comparison of light emission between La-RL and La-Luc2. 
366 BALB/c mice (n = 4) were inoculated with 106 La-RL or La-Luc2 promastigotes at the left hind 
367 footpad. Parasite burden was determined after 9 weeks of infection by bioimaging (A and B), 
368 limiting dilution (B) and ex vivo bioluminescence activity of amastigotes (C). Colours represent 
369 the same animal over different experiments. (D) Follow up of the lesion size. Data are the 
370 average and standard deviation of the biological replicates. 
371 
 
372 Aiming to avoid the influence of any differences in lesion development between the La- 
 
373 RL and La-Luc2 lines, mice were bioimaged 1 hour after inoculation with a fixed number of 
 
374 parasites. Freshly purified lesion-derived amastigotes or stationary phase-promastigotes were 
 





376 measured.  No  significant  differences  were  observed  between  footpads  inoculated  with 
 
377 amastigotes and promastigotes of the same line. The comparison of light intensity emitted by 
 
378 La-RL and La-Luc2 was also statistically identical, indicating equivalent in vivo detection for 
 





382 Figure 6. In vivo bioluminescence of 105  promastigotes or amastigotes of La-RL and 
383 La-Luc2. BALB/c mice (n = 2) were inoculated in the footpad with 105  promastigotes or 
384 amastigotes. Bioluminescence was evaluated 1-hour post-inoculation. Data are the average 
385 and standard deviation of the biological replicates. RLU: relative light units. 
386 
 
387 RL showed to be a promising viability reporter both in in vitro and in vivo assays. 
 
388 Unexpectedly, RL displayed sensitivity similar to Luc2 in our model, even though its light is 
 
389 emitted in a wavelength above 600 nm. According to Liang et al. (2012), Luc2 produces light 
 
390 in a broad spectrum of emission, from 540 to 640 nm. Although some of this light may be 
 
391 blocked by tissues, as with NL, part of it is emitted over 600 nm and therefore interference 
 
392 would be less important. On the other hand, in a model where skin lesions are being evaluated, 
 
393 less tissue barriers are present. Nevertheless, there is still room to investigate the use of this 
 





395 more tissue barriers. Our findings lead to the conclusion that, as observed for Luc2, RL was 
 




398 New  strategies  for  imaging  will  bring  great  benefits  onto  biological  preclinical 
 
399 evaluation of drugs and diseases. Interesting avenues are being pursued by improving 
 
400 reporter enzymes as well as the bioluminescence properties of the substrates (Kuchimaru et 
 
401 al., 2016; Iwano et al., 2018), or both (Yeh et al., 2017). For example, a near infrared shift on 
 
402 emission obtained by a modified luciferase substrate resulted in great improvements in 
 
403 sensitivity of detection particularly from deep tissues (Kuchimaru et al., 2016) and even 
 
404 allowing detection of single cells in deep tissues of live animals (Iwano et al., 2018). These 
 
405 tools are beginning to be employed to study the relationship between parasites and their hosts 
 




408 4. Conclusion 
 
409 Altogether, these findings bring new insights regarding the use of modified luciferases 
 
410 in the drug  discovery  process for infectious diseases.  NL demonstrated  strong  in vitro 
 
411 bioluminescence and higher stability over the other luciferases. However, its application might 
 
412 be somewhat restricted to in vitro experiments here unexplored, whereas Luc2 and RL have 
 
413 apparently greater in vivo application, even though their light emission in vitro is less intense 
 
414 than NL. All luciferases, except for NL, showed to be useful tools in the report of intracellular 
 
415 amastigotes viability. Finally, we have demonstrated that a red-shifted luciferase does not 
 
416 enhance  light  detection  in  a  cutaneous  leishmaniasis  model,  displaying  similar  in  vivo 
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Figure S1. Lesion development in BALB/c mice infected with L. amazonensis WT and 
mutants expressing NL, NLP and RL. Animals (n = 3) were infected with 3x106 stationary- 
phase promastigotes and lesion development was monitored weekly from the 5th week post- 
infection with a caliper. Data represents the difference between the size of infected and 




Figure S2. Luminescence of L. amazonensis promastigotes expressing NL, NLP, RL 
and Luc2. Promastigotes were serially diluted (logarithmic base) and luminescence was 
measured using a microplate reader 10, 40 and 60 minutes after substrate addition. Results 
are the mean and standard deviation of a representative experiment of three independent 








Figure S3. Susceptibility of La-NL and La-Luc2 lines to amphotericin B determined by 
luminescence. Promastigotes were treated in triplicates with increasing concentrations of 
amphotericin B for 24 hours in white 96-well plates. Adequate substrates were added, and 
luminescence was  obtained  after  10  minutes. Data represents the mean  and  standard 






Figure S4. Susceptibility of La-NLP, La_RL and La-Luc2 intramacrophage amastigotes 
determined by luminescence. Macrophages infected with La-NLP, La-RL and La-Luc2 were 
treated with increasing concentrations of miltefosine for 72 hours. Data are mean and standard 
deviation of a representative experiment of three independent experiments. 
